Hemophilia News

BioRx Introduces National Physical Therapy Program for Patients with Hemophilia

CINCINNATI, Ohio (February 19, 2013) – BioRx announced today the launch of a new physical therapy program to help patients, physicians, physical therapists, and health insurers manage the complications and costs of hemophilia-related joint damage. The program, called REBUILD, supports a patient’s physical therapy program at the local level ... read more »

BioRx Receives Limited Distribution Rights to Corifact® for the Treatment of Congenital Factor XIII Deficiency

Cincinnati, Ohio (July 11, 2012) — BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Corifact® [Factor XIII Concentrate (Human)], manufactured by CSL Behring. Corifact is the only FDA-approved treatment for congenital Factor XIII (FXIII) deficiency, reported to be one of the rarest bleeding disorders in the world ... read more »

BioRx Acquires Coagulife Pharmacy

Cincinnati, Ohio (July 9, 2012) - BioRx announced today that it has acquired Coagulife Pharmacy, a specialized provider of clotting factor medications and supplies for the treatment of hemophilia and related bleeding disorders ... read more »

BioRx Scholarship Applications Are Now Being Accepted!

BioRx and Hemophilia of North Carolina announce the availability of multiple BioRx Educational Scholarships, in the amount of $500 to $3,000 each, to individuals with bleeding disorders*. The deadline for submitting applications is May 1. At least one scholarship will be awarded to an applicant pursuing education in a health related field.

For more information, click here.

Scholarships are intended for persons affected by a bleeding disorder*, including anyone who

has been diagnosed with a bleeding disorder; or
is a caregiver of a child or adult affected by a bleeding disorder; or
has a sibling or parent in the same household affected by a bleeding disorder.

*For the purpose of this scholarship application, the term “bleeding disorder” is limited to clotting factor deficiency disorders, specifically: hemophilia A, B, and C; von Willebrand Disease; and factor V (parahemophilia), factor VII, factor X, and factor XIII deficiencies.

BioRx recognized by Smart Business for Hemophilia Philanthropy

Both Philip Rielly and Eric Hill look to find any way they can to contribute to the worthy causes that support the patient communities the company serves. Rielly, president and co-founder, and Hill, vice president and co-founder of BioRx LLC, understand their mission as a health care provider is to give back whenever and wherever possible. (© Smart Business Network Inc.) ... read more »